Tenpoint Therapeutics Ltd
Tenpoint Therapeutics Ltd is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Tenpoint Therapeutics Ltd.
Tenpoint Therapeutics Ltd is a company.
Key people at Tenpoint Therapeutics Ltd.
Tenpoint Therapeutics Ltd is a commercial-ready biotechnology company developing paradigm-shifting treatments to rejuvenate vision in the aging eye, targeting high-need ophthalmic conditions like presbyopia, cataracts, and geographic atrophy.[1][5] Its lead product, BRIMOCHOL PF, is a novel pupil-modulating investigational therapeutic addressing presbyopia—a near-vision loss affecting nearly 128 million U.S. adults—with Phase 3 trials (BRIO-I and BRIO-II) completed, an NDA filed, and FDA PDUFA date set for January 28, 2026.[1] The company serves patients and eye care professionals, solving age-related vision decline through innovative therapies, backed by a leadership team experienced in blockbuster ophthalmic approvals; it shows strong growth momentum via recent trial successes and partnerships, such as with Visus Therapeutics.[1][2]
Headquartered in Irvine, California (with UK roots and additional offices), Tenpoint employs 77 people and focuses on engineered cell-based therapies and in vivo reprogramming for permanent vision restoration in degenerative diseases.[1][2][3]
Tenpoint Therapeutics Limited was incorporated on September 7, 2020, in the UK (initially as Tenzing Therapeutics Limited, renamed by November 2020), with its registered office in Altrincham, Cheshire.[4] It launched publicly with a $70 million Series A financing led by Sofinnova Partners, shifting focus from early engineered cell-based vision restoration to commercial-ready ophthalmics like BRIMOCHOL PF.[2] Pivotal early traction included positive topline data from the Phase 3 BRIO-II study and a merger-like collaboration with Visus Therapeutics to build first-in-class eye medicines, building on 2019 precursors noted in some profiles.[1][2] Founders and specific leadership details emphasize ophthalmic veterans with commercialization expertise, humanizing the mission to address vision loss at its cellular root.[1]
Tenpoint rides the aging population megatrend, where presbyopia alone impacts 128 million U.S. adults amid rising demand for non-surgical vision restoration.[1] Timing aligns with biotech advances in pupil modulation and cell reprogramming, fueled by market forces like expanding ophthalmic pipelines (e.g., post-COVID eye care backlogs) and investor interest in late-stage assets—evident in its Series A and partnerships.[2] It influences the ecosystem by accelerating "best-and-first-in-class" medicines via collaborations like Visus, bridging UK/EU biotech origins to U.S. commercialization hubs, and advancing biopharma's shift toward regenerative eye therapies.[1][2][4]
With PDUFA looming January 28, 2026, Tenpoint is poised for potential approval and launch of BRIMOCHOL PF, unlocking blockbuster revenue in presbyopia while expanding its pipeline into cataracts and atrophy.[1] Trends like AI-driven drug discovery, gene editing synergies, and global aging (e.g., 2 billion+ affected by 2030) will propel its cell-based innovations, potentially evolving it into a multi-asset ophthalmic leader through further partnerships or acquisitions.[1][2] This positions Tenpoint to redefine aging-eye care, directly fulfilling its mission to rejuvenate vision at scale.[5]
Key people at Tenpoint Therapeutics Ltd.
